Two More Phase III Zactima Trials Reach Full Enrollment
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca’s investigational drug for non-small cell lung cancer remains on track for an NDA filing this year.
You may also be interested in...
AstraZeneca’s Zactima Submission Delayed, Anti-Thrombotic Moves To Phase III
Firm now expects to make vandetanib submission for non-small cell lung cancer in first half of 2009.
AstraZeneca’s Zactima Submission Delayed, Anti-Thrombotic Moves To Phase III
Firm now expects to make vandetanib submission for non-small cell lung cancer in first half of 2009.
AstraZeneca Executive VP, Discovery Research, Jan Lundberg: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
AstraZeneca's chief of discovery research discusses his company's pipeline, its plans related to the acquisitions of MedImmune and CAT, and whether the Exanta compound has any developmental future with "The Pink Sheet" DAILY.